ArticleOncotarget2015
The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Altered long noncoding RNAs and survival outcomes in ovarian cancer: A systematic review and meta-analysis (PRISMA Compliant).Medicine · 2018Pooled it
- Meta-signature LncRNAs serve as novel biomarkers for colorectal cancer: integrated bioinformatics analysis, experimental validation and diagnostic evaluation.Scientific reports · 2017Trial
- Exploring the Role of Long Noncoding RNAs (lncRNAs) as Biomarkers in Cancers.Experientia supplementum (2012) · 2026Review
- The Clinical Significance ofInternational journal of molecular sciences · 2024Article
- A Multi-Faceted Analysis ShowingInternational journal of molecular sciences · 2024Article
- Expression and clinical significance of lncRNA BC041954 in ovarian cancer.Experimental and therapeutic medicine · 2022Article
- LncRNA CRNDE promotes cell proliferation, migration and invasion of ovarian cancer via miR-423-5p/FSCN1 axis.Molecular and cellular biochemistry · 2022Article
- Long Noncoding RNA CRNDE Functions as an Oncogene to Facilitate Aggressive Behaviors of Nasopharyngeal Carcinoma Cells by Modulating miR-3163/TWIST1 Axis.Molecular biotechnology · 2022Article
- Article
- ceRNA Network Analysis Shows That lncRNA CRNDE Promotes Progression of Glioblastoma Through Sponge mir-9-5p.Frontiers in genetics · 2021Article
- Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.Journal of Cancer · 2021Review
- Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs.Cancers · 2020Review
- Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/β-catenin pathway.Bioscience reports · 2020Article
- Effects and Mechanism of lncRNA CRNDE on Sepsis-Induced Acute Kidney Injury.Analytical cellular pathology (Amsterdam) · 2020Article
- CRNDE: an oncogenic long non-coding RNA in cancers.Cancer cell international · 2020Review
- MEG3: an Oncogenic Long Non-coding RNA in Different Cancers.Pathology oncology research : POR · 2019Review
- Overexpressed long noncoding RNA CRNDE with distinct alternatively spliced isoforms in multiple cancers.Frontiers of medicine · 2019Article
- Long non-coding RNA CRNDE regulates cell proliferation, migration, invasion, epithelial-mesenchymal transition and apoptosis in oral squamous cell carcinoma.Oncology letters · 2019Article
- Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.Cancer biology & therapy · 2019Article
- Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CRNDE gene seems to play an oncogenic role in cancers, though its exact function remains unknown. Here, we tried to assess its usefulness as a molecular prognostic marker in ovarian cancer. Based on results of our microarray studies, CRNDE transcripts were further analyzed by Real-Time qPCR-based profiling of their expression. The qPCR study was conducted with the use of personally designed TaqMan assays on 135 frozen tissue sections of ovarian carcinomas from patients treated with platinum compounds and either cyclophosphamide (PC, N = 32) or taxanes (TP, N = 103). Elevated levels of two different CRNDE transcripts were a negative prognostic factor; they increased the risk of death and recurrence in the group of patients treated with TP, but not PC (DNA-damaging agents only). Higher associations were found for overexpression of the short CRNDE splice variant (FJ466686): HR 6.072, 95% CI 1.814-20.32, p = 0.003 (the risk of death); HR 15.53, 95% CI 3.812-63.28, p < 0.001 (the risk of recurrence). Additionally, accumulation of the TP53 protein correlated with decreased expression of both CRNDE transcripts in tumor cells. Our results depict CRNDE as a potential marker of poor prognosis in women with ovarian carcinomas, and suggest that its significance depends on the therapeutic regimen used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.